GlassScriptPhysician profile
Lindsey M Lawrence
NPI 1477050607
$9,349.07
in general payments reported to CMS, 2019-2025
26 companies · $1,461 in 2025
The $1,461 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,041 · 2022: $1,617 · 2023: $3,086 · 2024: $2,145 · 2025: $1,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,601 · Education: $90.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,600.94 |
| Education | $90.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,441.50 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $1,242.52 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $1,211.84 | 2021-2024 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $978.13 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $833.80 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $738.00 | 2022-2024 | Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $706.81 | 2021-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $670.54 | 2021-2025 | Fanapt, Hetlioz |
| Braeburn INC. | $202.73 | 2024-2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $165.70 | 2024-2025 | Cobenfy |
| Corium, LLC | $159.50 | 2023-2024 | Azstarys |
| Axsome Therapeutics, INC. | $141.68 | 2023-2025 | Auvelity, Symbravo |
| Supernus Pharmaceuticals, INC. | $138.27 | 2024-2025 | Qelbree |
| Horizon Therapeutics Plc | $124.77 | 2021 | |
| Amgen INC. | $124.46 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $112.21 | 2023-2025 | Rexulti |
| Indivior INC. | $103.18 | 2023-2024 | Perseris, Sublocade |
| Sunovion Pharmaceuticals INC. | $91.62 | 2022 | |
| Ironshore Pharmaceuticals INC. | $31.12 | 2024 | |
| Idorsia Pharmaceuticals US INC | $22.24 | 2023 | Quviviq |
| Luye Pharma (USA) LTD. | $20.54 | 2025 | Erzofri Extended-Release |
| Uswm, LLC | $20.08 | 2022 | |
| Lilly USA, LLC | $19.75 | 2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $18.36 | 2021 | |
| Noven Therapeutics, LLC | $14.87 | 2024 | Xelstrym |
| Neos Therapeutics, LP | $14.85 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.